Evidence map›Paper›PMID 36978414›Full record

ArticleAntibiotics (Basel, Switzerland)2023

Spread of

Xenia Vázquez, Javier Fernández, Miriam Alkorta, María de Toro, M Rosario Rodicio, Rosaura Rodicio

Open access · goldFull text read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Emergence ofFrontiers in microbiology · 2026
    Article
  4. Multidrug resistance inApplied and environmental microbiology · 2024
    Article
  5. Genomic characterization ofFrontiers in microbiology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Xenia VázquezDepartamento de Biología Funcional, Área de Microbiología, Universidad de Oviedo (UO), 33006 Oviedo, Spain.
Javier FernándezGrupo de Microbiología Traslacional, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.
Miriam AlkortaServicio de Microbiología, Hospital Universitario de Donostia (HUD)-IIS Biodonostia, 20014 San Sebastián, Spain.
María de ToroPlataforma de Genómica y Bioinformática, Centro de Investigación Biomédica de La Rioja (CIBIR), 26006 Logroño, Spain.ORCID 0000-0003-3329-0203
M Rosario RodicioDepartamento de Biología Funcional, Área de Microbiología, Universidad de Oviedo (UO), 33006 Oviedo, Spain.ORCID 0000-0002-3402-2908
Rosaura RodicioGrupo de Microbiología Traslacional, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.
Universidad de Oviedo · ESBiogipuzkoa Health Research Institute · ESCenter for Biomedical Research of La Rioja · ESCentro de Investigación Biomédica en Red de Enfermedades Respiratorias · ES

Funding

Instituto de Salud Carlos III FIS PI17/00474
6 · The paper itself

Abstract

The monophasic 4,[5],12:i:-variant of

Indexed as

antimicrobial drug resistanceblaCTX-M-9complex class 1 integronIncHI2ISCRmcr-9qnrA1RR chromosomal resistance regionSalmonella genomic island 4

Identifiers

PMID36978414
PMCPMC10044134
OpenAlexW4323668948

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read24
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.